DiaMedica Therapeutics
DMAC
41 hedge funds and large institutions have $52.1M invested in DiaMedica Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
14% more funds holding
Funds holding: 36 → 41 (+5)
1.61% less ownership
Funds ownership: 31.93% → 30.32% (-1.6%)
14% less capital invested
Capital invested by funds: $60.6M → $52.1M (-$8.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$686K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$621K |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$592K |
| 4 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
+$420K |
| 5 |
Renaissance Technologies
New York
|
+$371K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$3.39M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.31M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$671K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$336K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$190K |
DMAC Hedge Fund Activity: Q1 2021 in Review
41 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2021, worth a combined $52.1M — down 14% from $60.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMAC positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $686K. The largest seller was Granite Point Capital Management, cutting an estimated $3.39M.
- 41 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2021, up from 36 in Q4 2020.
- Funds reported $52.1M of DiaMedica Therapeutics stock for Q1 2021, down 14% quarter-over-quarter.
- 10 funds opened new DiaMedica Therapeutics positions in Q1 2021 and 5 closed out, a net change of +5 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2021 was Stonepine Capital Management, an estimated $686K added.
- The largest DiaMedica Therapeutics seller in Q1 2021 was Granite Point Capital Management, an estimated $3.39M sold.
Based on aggregated 13F filings for Q1 2021.